Sunitinib therapy for imatinib-resistant and/or intolerant gastrointestinal stromal tumors: comparison of safety and efficacy between standard and reduced dosage regimens.
Sign Up to like & getrecommendations! Published in 2023 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyac202
Abstract: BACKGROUND Sunitinib therapy for patients with imatinib-resistant and/or intolerant gastrointestinal stromal tumors (GISTs) often causes severe adverse events (AEs) that lead to treatment discontinuation. METHODS We retrospectively reviewed the clinical records of imatinib-resistant and/or intolerant… read more here.
Keywords: dosage; reduced dosage; dosage group; sunitinib therapy ... See more keywords